Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
21-40 of 1,738 trials

Type 1 Diabetes: Frexalimab Treatment Study

We are studying a new medication, frexalimab, to see if it helps preserve insulin production in young people with newly diagnosed type 1 diabetes. Participants will receive either the medication or a placebo while continuing their insulin therapy.

Type 1 Diabetes1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesEndocrinologyInternal Medicine

Diabetic Foot Ulcers: Phage Therapy Study

We are comparing standard treatment with phage therapy against standard treatment plus a placebo for diabetic foot ulcers infected by Staphylococcus aureus. This study aims to see if phage therapy can improve healing.

Diabetic Foot Ulcer1-2 yearsSafety phase (I)Efficacy phase (II)DiabetologyInfectious DiseasesInternal Medicine

Individualized Immunotherapy for Early-Stage Hodgkin Lymphoma

We are testing a new personalized treatment using tislelizumab for adults with early-stage unfavorable classical Hodgkin lymphoma. The goal is to see if this approach improves treatment outcomes and is safe for patients.

Early-Stage Unfavorable Classical Hodgkin Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Waldenström’s Macroglobulinemia: Venetoclax with Rituximab

We are studying whether the combination of Venetoclax and Rituximab is more effective than standard treatments for patients with Waldenström’s Macroglobulinemia. This research aims to find better options for managing this condition.

Waldenström's Macroglobulinemia1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Xenon Treatment for Brain Injury After Aneurysmal Subarachnoid Hemorrhage

We are investigating whether xenon gas can help protect the brain and improve recovery in patients who have experienced a specific type of brain bleed. This study will also look at the safety and effects of xenon on neurological outcomes.

Aneurysmal Subarachnoid Hemorrhage6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurology

Ikervis for Atopic Keratoconjunctivitis

We are studying whether Ikervis, applied four times a day, can effectively treat atopic keratoconjunctivitis. This trial aims to see how well it works compared to a placebo.

Atopic Keratoconjunctivitis3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementOphthalmology

MRSA Treatment: Povidone Iodine Nasal Kit

We are evaluating a nasal decolonization kit with povidone iodine for patients with MRSA. The study aims to see how well it reduces MRSA levels and how patients feel about using it.

MRSA Infection>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesDermatologyInfectious Diseases

Hepatocellular Carcinoma: New Vaccine with Atezolizumab and Bevacizumab

We are studying a new cancer vaccine combined with two existing treatments for patients with unresectable liver cancer. The goal is to see if this combination improves survival and quality of life.

Non-resectable Hepatocellular Carcinoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHepatologyInternal MedicineOncology

Immunotherapy for Early dMMR Rectal Cancer

We are studying the effects of nivolumab and ipilimumab in patients with stage 1-3 dMMR rectal cancer. The goal is to see how effective and tolerable this treatment is.

Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Oligometastatic Solid Cancer: SBRT with ATRA Support

We are studying a new radiation therapy combined with a drug to support the immune system in patients with oligometastatic solid cancer. This trial aims to evaluate safety and how well the treatment works.

Oligometastatic Solid Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementOncology

Chronic Kidney Disease: Amiloride Treatment Study

We are investigating whether the diuretic amiloride can help protect kidney function in people with chronic kidney disease. The study looks at its effects on kidney health and inflammation.

Chronic Kidney Disease≤3 monthsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Duchenne Muscular Dystrophy: SQY51 Treatment Study

We are studying the safety and effects of a new treatment called SQY51 in children and adults with Duchenne Muscular Dystrophy. The goal is to see how it impacts muscle function and overall well-being.

Duchenne Muscular Dystrophy1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOrthopedics and Traumatology

Post-Cardiac Arrest Shock: High-Dose Vitamin C Study

We are investigating whether early intravenous high-dose vitamin C can help patients who have suffered a cardiac arrest and are in shock. The study aims to see if this treatment reduces the need for blood pressure support and improves survival and recovery.

Cardiac Arrest6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Diabetic Neuropathic Pain: Incobotulinumtoxin-A Injections

We are studying whether injections of incobotulinumtoxin-A can help relieve pain in people with diabetic neuropathic pain in their lower extremities. The trial will also look at how this treatment affects daily activities and overall quality of life.

Diabetic Peripheral Neuropathic Pain6-12 monthsEfficacy phase (II)Standard MedicinesDiabetologyEndocrinologyNeurology

HER2+ Breast Cancer: Tucatinib with Oral Etoposide and Trastuzumab

We are studying a new treatment combining tucatinib, oral etoposide, and trastuzumab for patients with metastatic HER2+ breast cancer who have not responded to prior therapies. The goal is to see if this combination improves treatment outcomes and safety.

Metastatic HER2+ Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Salivary Duct Carcinoma: Dutasteride with Combined Androgen Blockade

We are studying whether adding dutasteride to standard therapy helps patients with recurrent or metastatic salivary duct carcinoma. The trial also looks at safety and quality of life for those receiving this new treatment.

Salivary Duct CarcinomaEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Geographic Atrophy: JNJ-81201887 Treatment Study

We are examining the long-term safety and tolerability of JNJ-81201887 for people with geographic atrophy from age-related macular degeneration. This study follows participants from earlier trials to gather more information.

Geographic Atrophy>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteOphthalmology

Heart Attack Treatment: Methylprednisolone Study

We are investigating whether a steroid given before hospital treatment can reduce heart damage in patients with a heart attack. This study aims to improve heart function and decrease inflammation after the event.

Heart Attack1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Morphine Study in Obesity and Sleep Apnea Patients

We are investigating how obesity and obstructive sleep apnea influence the effects of morphine for pain relief. This research aims to improve pain management for patients, especially those having bariatric surgery.

Obesity Surgery>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementEndocrinologyInternal MedicineOrthopedics and TraumatologyOtolaryngologyPsychiatry

Multiple Myeloma: Anti-BCMA CAR T Cell Therapy

We are studying a new CAR T cell treatment for patients with relapsed or refractory Multiple Myeloma. The trial aims to evaluate its safety and effectiveness in improving patient outcomes.

Relapsed/Refractory Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology